Cargando…
Profile of conbercept in the treatment of neovascular age-related macular degeneration
In developed countries, age-related macular degeneration (AMD) is the leading cause of irreversible blindness in individuals over the age of 65 years. Vascular endothelial growth factor (VEGF) plays a vital role in the formation of neovascular AMD. VEGF regulates angiogenesis, enhances vascular perm...
Autores principales: | Lu, Xinmin, Sun, Xiaodong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4410828/ https://www.ncbi.nlm.nih.gov/pubmed/25960634 http://dx.doi.org/10.2147/DDDT.S67536 |
Ejemplares similares
-
Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis
por: Wang, Luping, et al.
Publicado: (2018) -
Metabolomics study of treatment response to conbercept of patients with neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
por: Shen, Yinchen, et al.
Publicado: (2022) -
Conbercept for Treatment of Neovascular Age-Related Macular Degeneration and Visual Impairment due to Diabetic Macular Edema or Pathologic Myopia Choroidal Neovascularization: A Systematic Review and Meta-Analysis
por: Zhou, Pengxiang, et al.
Publicado: (2021) -
Short-Term Results of Switch from Conbercept to Bevacizumab or Ranibizumab in Eyes with Persistent Neovascular Age-Related Macular Degeneration
por: Wang, Zongyi, et al.
Publicado: (2020) -
Conbercept for patients with age-related macular degeneration: a systematic review
por: Zhang, Jiaxing, et al.
Publicado: (2018)